Masking of antigenic epitopes by antibodies shapes the humoral immune response to influenza

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 370, Issue 1676, 2015, Pages

  Zarnitsyna, Veronika I ^a   Ellebedy, Ali H ^a,b   Davis, Carl ^a,b   Jacob, Joshy ^a,b   Ahmed, Rafi ^a,b   Antia, Rustom ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Epitope masking model; Humoral immunity; Influenza; Strain variation

Indexed keywords

ANTIBODY; ANTIGEN; BODY FLUID; DRUG DEVELOPMENT; GENETIC VARIATION; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA; PROTEIN;

INFLUENZA A VIRUS;

EPITOPE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY; VIRUS ANTIGEN;

B LYMPHOCYTE; BIOLOGICAL MODEL; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; INFLUENZA; MATHEMATICAL PHENOMENA; ORTHOMYXOVIRIDAE; VIROLOGY;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; B-LYMPHOCYTES; EPITOPES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNITY, HUMORAL; INFLUENZA, HUMAN; MATHEMATICAL CONCEPTS; MODELS, IMMUNOLOGICAL; ORTHOMYXOVIRIDAE;

EID: 84937696312     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2014.0248     Document Type: Article

References (59)

1. Grebe KM, Yewdell JW, Bennink JR. 2008 Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect. 10, 1024-1029. (doi:10.1016/j.micinf.2008.07.002)
2. Yewdell JW. 2011 Viva la revolucio´n: rethinking influenza a virus antigenic drift. Curr. Opin. Virol. 1, 177-183. (doi:10.1016/j.coviro.2011.05.005)
3. Ferguson NM, Galvani AP, Bush RM. 2003 Ecological and immunological determinants of influenza evolution. Nature 422, 428-433. (doi:10.1038/ nature01509)
4. Koelle K, Cobey S, Grenfell B, Pascual M. 2006 Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans. Science 314, 1898-1903. (doi:10.1126/science. 1132745)
5. Taubenberger JK. 2006 Influenza hemagglutinin attachment to target cells: 'birds do it, we do it. . .'. Future Virol. 1, 415-418. (doi:10.2217/ 17460794.1.4.415)
6. Wrammert J et al. 2011 Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181-193. (doi:10.1084/ jem.20101352)
7. Das SR et al. 2013 Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection. Cell Host Microbe 13, 314-323. (doi:10.1016/j.chom.2013. 02.008)
8. Schmidt C. 2013 Vaccines for pandemics. Nat. Biotechnol. 31, 957-960. (doi:10.1038/nbt.2733)
9. Brooke CB, Yewdell JW. 2013 Host versus flu: antibodies win a round? Nat. Struct. Mol. Biol. 20, 245-246. (doi:10.1038/nsmb.2524)
10. Chiu C, Ellebedy AH, Wrammert J, Ahmed R. 2015 B cell responses to influenza infection and vaccination. Curr. Top. Microbiol. Immunol. 386, 381-398.
11. Wrigley NG. 1979 Electron microscopy of influenza virus. Br. Med. Bull. 35, 35-38.
12. Taylor HP, Armstrong SJ, Dimmock NJ. 1987 Quantitative relationships between an influenza virus and neutralizing antibody. Virology 159, 288-298. (doi:10.1016/0042-6822(87)90466-1)
13. Bouvier NM, Palese P. 2008 The biology of influenza viruses. Vaccine 26(Suppl. 4), D49-D53. (doi:10. 1016/j.vaccine.2008.07.039)
14. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. 1992 Evolution and ecology of influenza A viruses. Microbiol. Rev. 56, 152-179.
15. Air GM. 1981 Sequence relationships among the hemagglutinin genes of 12 subtypes of influenza A virus. Proc. Natl Acad. Sci. USA 78, 7639-7643. (doi:10.1073/pnas.78.12.7639)
16. Nobusawa E, Aoyama T, Kato H, Suzuki Y, Tateno Y, Nakajima K. 1991 Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology 182, 475-485. (doi:10.1016/ 0042-6822(91)90588-3)
17. Wu Y, Wu Y, Tefsen B, Shi Y, Gao GF. 2014 Batderived influenza-like viruses H17N10 and H18N11. Trends Microbiol. 22, 183-191. (doi:10.1016/j.tim. 2014.01.010)
18. Okuno Y, Isegawa Y, Sasao F, Ueda S. 1993 A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67, 2552-2558.
19. Okuno Y, Matsumoto K, Isegawa Y, Ueda S. 1994 Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J. Virol. 68, 517-520.
20. Throsby M et al. 2008 Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgMþ memory B cells. PLoS ONE 3, e3942. (doi:10.1371/ journal.pone.0003942)
21. Corti D et al. 2010 Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120, 1663-1673. (doi:10.1172/JCI41902)
22. Corti D et al. 2011 A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856. (doi:10.1126/science.1205669)
23. Ekiert DC, Bhabha G, Elsliger MA, Friesen RHE, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. 2009 Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251. (doi:10.1126/science.1171491)
24. Ekiert DC et al. 2011 A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843-850. (doi:10.1126/science.1204839)
25. Kucharski AJ, Lessler J, Read JM, Zhu H, Jiang CQ, Guan Y, Cummings DAT, Riley S. 2015 Estimating the life course of influenza A(H3N2) antibody responses from cross-sectional data. PLoS Biol. 13, e1002082. (doi:10.1371/journal.pbio.1002082)
26. Francis Jr T. 1955 The current status of the control of influenza. Ann. Intern. Med. 43, 534-538. (doi:10.7326/0003-4819-43-3-534)
27. Francis T. 1960 On the doctrine of original antigenic sin. Am. Phil. Soc. 104, 572-578.
28. Davenport FM, Hennessy AV, Francis Jr T. 1953 Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J. Exp. Med. 98, 641-656. (doi:10. 1084/jem.98.6.641)
29. Davenport FM, Hennessy AV. 1956 A serologic recapitulation of past experiences with influenza A; antibody response to monovalent vaccine. J. Exp. Med. 104, 85-97. (doi:10.1084/jem.104.1.85)
30. Jensen KE, Davenport FM, Hennessy AV, Francis Jr T. 1956 Characterization of influenza antibodies by serum absorption. J. Exp. Med. 104, 199-209. (doi:10.1084/jem.104.2.199)
31. Fazekas de St G, Webster RG. 1966 Disquisitions of original antigenic sin. I. Evidence in man. J. Exp. Med. 124, 331-345. (doi:10.1084/jem. 124.3.331)
32. Kim JH, Skountzou I, Compans R, Jacob J. 2009 Original antigenic sin responses to influenza viruses. J. Immunol. 183, 3294-3301. (doi:10.4049/ jimmunol.0900398)
33. Kim JH, Davis WG, Sambhara S, Jacob J. 2012 Strategies to alleviate original antigenic sin responses to influenza viruses. Proc. Natl Acad. Sci. USA 109, 13 751-13 756. (doi:10.1073/pnas. 0912458109)
34. Lessler J, Riley S, Read JM, Wang S, Zhu H, Smith GJD, Guan Y, Jiang CQ, Cummings DAT. 2012 Evidence for antigenic seniority in influenza A (H3N2) antibody responses in southern China. PLoS Pathog. 8, e1002802. (doi:10.1371/journal.ppat. 1002802)
35. Fonville JM et al. 2014 Antibody landscapes after influenza virus infection or vaccination. Science 346, 996-1000. (doi:10.1126/science.1256427)
36. Tan GS, Lee PS, Hoffman RMB, Mazel-Sanchez B, Krammer F, Leon PE, Ward AB, Wilson IA, Palese P. 2014 Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J. Virol. 88, 13 580-13 592. (doi:10.1128/JVI.02289-14)
37. Wei CJ et al. 2010 Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329, 1060-1064. (doi:10.1126/science.1192517)
38. Kanekiyo M et al. 2013 Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102-106. (doi:10. 1038/nature12202)
39. Krammer F, Pica N, Hai R, Margine I, Palese P. 2013 Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87, 6542-6550. (doi:10.1128/ JVI.00641-13)
40. Margine I et al. 2013 Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J. Virol. 87, 10 435-10 446. (doi:10.1128/JVI.01715-13)
41. Krammer F, Margine I, Hai R, Flood A, Hirsh A, Tsvetnitsky V, Chen D, Palese P. 2014 H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J. Virol. 88, 2340-2343. (doi:10.1128/JVI.03183-13)
42. Ellebedy AH et al. 2014 Induction of broadly crossreactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc. Natl Acad. Sci. USA 111, 13 133-13 138. (doi:10.1073/pnas.1414070111)
43. Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F. 2014 Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J. Virol. 88, 13 260-13 268. (doi:10.1128/JVI.02133-14)
44. Arinaminpathy N, Ratmann O, Koelle K, Epstein SL, Price GE, Viboud C, Miller MA, Grenfell BT. 2012 Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza. Proc. Natl Acad. Sci. USA 109, 3173-3177. (doi:10.1073/pnas.1113342109)
45. Antia R, Levin BR, May RM. 1994 Within-host population-dynamics and the evolution and maintenance of microparasite virulence. Am. Nat. 144, 457-472. (doi:10.1086/285686)
46. Oprea M, Perelson AS. 1996 Exploring the mechanisms of primary antibody responses to T cell-dependent antigens. J. Theor. Biol. 181, 215-236. (doi:10.1006/jtbi.1996.0127)
47. Slifka MK, Antia R, Whitmire JK, Ahmed R. 1998 Humoral immunity due to long-lived plasma cells. Immunity 8, 363-372. (doi:10.1016/S1074- 7613(00)80541-5)
48. Hovden AO, Cox RJ, Haaheim LR. 2005 Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand. J. Immunol. 62, 36-44. (doi:10.1111/j.1365- 3083.2005.01633.x)
49. Taylor HP, Dimmock NJ. 1994 Competitive binding of neutralizing monoclonal and polyclonal IgG to the HA of influenza A virions in solution: only one IgG molecule is bound per HA trimer regardless of the specificity of the competitor. Virology 205, 360-363. (doi:10.1006/viro.1994.1653)
50. Poumbourios P, Brown LE, White DO, Jackson DC. 1990 The stoichiometry of binding between monoclonal antibody molecules and the hemagglutinin of influenza virus. Virology 179, 768-776. (doi:10.1016/0042-6822(90)90144-G)
51. Hilborn R, Mangel M. 1997 The ecological detective: confronting models with data. Monographs in population biology 28. Princeton, NJ: Princeton University Press.
52. May RM. 2004 Uses and abuses of mathematics in biology. Science 303, 790-793. (doi:10.1126/ science.1094442)
53. Gerhard W, Yewdell J, Frankel ME, Webster R. 1981 Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290, 713-717. (doi:10.1038/290713a0)
54. Kepler TB, Perelson AS. 1993 Cyclic re-entry of germinal center B cells and the efficiency of affinity maturation. Immunol. Today 14, 412-415. (doi:10. 1016/0167-5699(93)90145-B)
55. Zhang Y et al. 2013 Germinal center B cells govern their own fate via antibody feedback. J. Exp. Med. 210, 457-464. (doi:10.1084/jem. 20120150)
56. Handel A, Longini Jr IM, Antia R. 2010 Towards a quantitative understanding of the within-host dynamics of influenza A infections. J. R. Soc. Interface 7, 35-47. (doi:10.1098/rsif.2009.0067)
57. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS. 2006 Kinetics of influenza A virus infection in humans. J. Virol. 80, 7590-7599. (doi:10.1128/JVI.01623-05)
58. Saenz RA et al. 2010 Dynamics of influenza virus infection and pathology. J. Virol. 84, 3974-3983. (doi:10.1128/JVI.02078-09)
59. Amanna IJ, Carlson NE, Slifka MK. 2007 Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903-1915. (doi:10. 1056/NEJMoa066092)